Afeletecan
Alternative Names: BAY 38-3441Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer
- Class Antineoplastics; Camptothecins; Dipeptides; Glycoconjugates
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
Most Recent Events
- 26 Nov 2002 Results from two phase I studies have been added to the adverse events and Cancer therapeutic trials sections
- 25 Nov 2002 A study has been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
- 10 Dec 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events section